University of Tokyo
Also known as: Department of Cardiovascular Medicine, University of Tokyo Graduate School of Medicine | Department of Gastroenterology, University of Tokyo | Department of Palliative Medicine, The University of Tokyo Hospital | Director, Research Hospital, Institute of Medical Science, Tokyo University | Division of Nephrology and Endocrinology University of Tokyo School of medicine | HONJO CLINIC II, Tokyo, Japan | Human Genome Center, Institute of Medical Science, University of Tokyo | Institute of Medical Science, The University of Tokyo | Professor, Department of Metabolic Diseases, Graduate School of Medicine, the University of Tokyo. | Professor, Department of Nephrology and Endocrinology, University of Tokyo Graduate School of Medicine | The Institutute of Medical Science, University of Tokyo | The University of Tokyo Hospital | Tokyo University
Highest phase reached
Phase 4
First clinical trial
Jul 1, 2002Last known activity
Apr 24, 2017
Timeline
1880s
- Jun 1, 1886
University of Tokyo— Founded
Drugs by trial phase (69 distinct, 67 trials)
Phase 4 (8 own, 0 via acquisition)
Phase 3 (6 own, 0 via acquisition)
Phase 2 (36 own, 0 via acquisition)
- cdca1
- perampanel
- gemcitabine
- hla-a*0201restricted urlc10 peptides with adjuvant
- hla-a*02:01-restricted vegfr1-derived peptide vaccination
- hla-a*2402 or a*0201 restricted peptides
- hla-a*2402restricted urlc10, cdca1, and kif20a peptides with adjuvant
- montanide isa51
- mt-3995
- panobinostat
- rnf43, tomm34, vegfr1, vegfr2 peptide vaccine
- tamibarotene
- s-488410
- s-588410
- s-1
- +21 more
Phase 1 (19 own, 0 via acquisition)
- antiangiogenic peptide vaccine therapy
- azd1656
- fluorouracil
- hla-a*0201 or hla-a*0206-restricted urlc10 peptides
- hla-a*2402-restricted cdca1 and kif20a peptides
- hla-a*2402restricted urlc10, cdca1, and kif20a peptides
- hla-a*2402restricted urlc10, cdca1, vegfr1 and vegfr2
- hla-a*2402restricted urlc10, ttk, vegfr1 and vegfr2
- hla-a02 restricted hig2
- ly6k, vegfr1, vegfr2
- ttk, ly6k, and imp-3 peptides
- cdca1, urlc10, kif20a, depdc1 and mphosph1
- co16
- her2/neu peptide
- egfrviii peptide
- +4 more
Indications
Studied for
- Amyotrophic Lateral Sclerosis
- Bile Duct Neoplasms
- Breast Neoplasms
- Carcinoma
- Carcinoma, Hepatocellular
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Renal Cell
- Cholangiocarcinoma
- Colorectal Neoplasms
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Diabetic Nephropathies
- Esophageal Neoplasms
- Essential Hypertension
- Glucose Intolerance
- Hepatitis
- Hepatitis A
- Hepatitis C
- Hepatitis C, Chronic
- Hepatitis, Chronic
- Hyperemia
- Hypertension
- Kidney Diseases
- Leukemia
- Leukemia-Lymphoma, Adult T-Cell
- Leukemia, T-Cell
- Lung Neoplasms
- Lymphoma
- Lymphoma, T-Cell
- Lymphoma, T-Cell, Cutaneous
- Macular Degeneration
- Motor Neuron Disease
- Neoplasm Metastasis
- Neoplasms
- Pancreatic Neoplasms
- Prostatic Neoplasms
- Rectal Neoplasms
- Recurrence
- Small Cell Lung Carcinoma
- Stomach Neoplasms
- Urinary Bladder Neoplasms
Recent trials (50)
- NCT03019419Study directorPhase 2Apr 24, 2017
- NCT02410369Reponsible party - principal investigatorPhase 2Mar 1, 2015
- NCT02410369Lead sponsorPhase 2Mar 1, 2015
- NCT02410369Overall official - principal investigatorPhase 2Mar 1, 2015
- NCT02354235Study directorPhase 3Jan 1, 2015
- NCT02354222Study directorPhase 3Jan 1, 2015
- NCT02220907Study directorPhase 3Aug 1, 2014
- NCT02205372Study directorPhase 1/Phase 2Jul 1, 2014
- NCT02081599Study directorPhase 4Jan 1, 2014
- NCT01889277Study directorPhase 1/Phase 2Jul 1, 2013
- NCT01592617CollaboratorPhase 2May 1, 2012
- NCT01950156CollaboratorPhase 1/Phase 2Sep 1, 2011
- NCT01949701CollaboratorPhase 1/Phase 2Aug 1, 2011
- NCT01301833Study directorPhase 3Feb 1, 2011
- NCT01227239Overall official - principal investigatorPhase 1/Phase 2Sep 1, 2010
Details
- Founded
- Tokyo, JP Jun 1, 1886
- Last known activity
- Apr 24, 2017